title: Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
authors.affiliation: Diabetes Centre, Isala Clinics, Zwolle, the Netherlands d.schrijnders@isala.nl.
authors.forename: Dennis
authors.initials: D
authors.lastname: Schrijnders
authors.affiliation: Diabetes Centre, Isala Clinics, Zwolle, the Netherlands Langerhans Medical Research Group, Zwolle, the Netherlands Department of General Practice, University Medical Center Groningen, Groningen, the Netherlands.
authors.forename: Sebastiaan T
authors.initials: ST
authors.lastname: Houweling
authors.affiliation: Diabetes Centre, Isala Clinics, Zwolle, the Netherlands Department of Internal Medicine, Isala Clinics, Zwolle, the Netherlands.
authors.forename: Gijs W D
authors.initials: GW
authors.lastname: Landman
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005247:Feeding Behavior; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D008687:Metformin